Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

#2900

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Aim(s): The objective was to evaluate survival outcomes after PRRT based on previous therapies

Materials and methods: The patients come from SEPTRALU registry in which 18 Spanish centers participate. Survival was estimated using Kaplan-Meier method. The effect of prognostic factors was evaluated by Cox models, adjusted by Ki67%, and stratified by the location of primary tumor

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,